ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
22.986,82
2,01%
S&P 500
5.638,94
2,13%
Dow Jones
41.488,19
1,65%
Euro vs US Dollar
1,09165
0,00%
Bitcoin
83.980,30
-0,43%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. Cel Sci Corporation New (CVM)

  7. Cel Sci Corporation New (CVM) News

CVM

Cel Sci (CVM)

Cel Sci Corporation New
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:CVM
DatumZeitQuelleÜberschriftSymbolFirma
20/02/202514h00Business WireCEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer TrialAMEX:CVMCel Sci Corporation New
18/02/202514h30Business WireCEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 WeeksAMEX:CVMCel Sci Corporation New
14/01/202515h00Business WireCEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck CancerAMEX:CVMCel Sci Corporation New
13/01/202522h16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:CVMCel Sci Corporation New
03/01/202523h25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CVMCel Sci Corporation New
02/01/202520h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
02/01/202520h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
02/01/202520h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
31/12/202422h15Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
31/12/202422h05Business WireCEL-SCI Announces Closing of $5 Million OfferingAMEX:CVMCel Sci Corporation New
30/12/202423h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
30/12/202422h16Edgar (US Regulatory)Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405AMEX:CVMCel Sci Corporation New
30/12/202402h41Business WireCEL-SCI Announces Pricing of $5 Million Public OfferingAMEX:CVMCel Sci Corporation New
27/12/202423h05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
27/12/202423h05Business WireCEL-SCI Announces Proposed Public Offering of Common StockAMEX:CVMCel Sci Corporation New
12/12/202415h15Business WireCEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer StudyAMEX:CVMCel Sci Corporation New
15/11/202422h30Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
13/11/202414h30Edgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
08/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CVMCel Sci Corporation New
07/11/202414h15Business WireU.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025AMEX:CVMCel Sci Corporation New
30/10/202422h21Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:CVMCel Sci Corporation New
25/10/202423h17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:CVMCel Sci Corporation New
22/10/202415h15Business WireFDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer PatientsAMEX:CVMCel Sci Corporation New
11/10/202423h00Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CVMCel Sci Corporation New
10/10/202422h05Edgar (US Regulatory)Form AW - Amendment Withdrawal RequestAMEX:CVMCel Sci Corporation New
08/10/202423h13Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]AMEX:CVMCel Sci Corporation New
01/10/202415h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
01/10/202415h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
01/10/202414h58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
01/10/202412h00Business WireCEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck CancerAMEX:CVMCel Sci Corporation New
 Showing the most relevant articles for your search:AMEX:CVM

Kürzlich von Ihnen besucht

AMEX
ATEK.WS
Athena Technology Acquis...
TG
ETBB
Bnp Paribas Easy Euro St...
NASDAQ
LANDM
Gladstone Land
NASDAQ
FEESX
Bmo Selecttrust Conserva...
CSE
FWM
Flow Metals
OKEX
BCDBTC
Bitcoin Diamond
DGFX
DAWNETH
Dawn
USOTC
FNMAK
Fannie Mae (QB)
NASDAQ
AMPX
Ampex
NASDAQ
FELYX
Bmo Sustainable Opportun...
NASDAQ
GGLL
Direxion Daily GOOGL Bul...
DOWI
DJTMNSV
DJ US Thematic Market Ne...
DGFX
WOOUSDT
WOO Network (Wootrade Network)
TG
SQWF
Republic of South Africa
DOWI
DWCHNDT
DJ Switzerland Total Sto...
NASDAQ
AONCW
American Oncology Network
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten

Werbung entfernen

Melden Sie sich für ein werbefreies Erlebnis an

Keine Werbung

Versuchen Sie es jetzt

Anzeigen behalten